For the second quarter of 2011, the company has posted net loss of $17.3m, or $0.19 loss per diluted share, compared to $4.06m, or $0.05 loss per diluted share, for the same period in 2010.
Loss from operations for the second quarter of 2011 was $20.06m, compared to $10.85m for the same period in 2010.
For the six months ended 30 June 2011, the company reported total revenues of $12.61m, compared to $12.86m for the same period in 2010.
Loss from operations was $39.82m for the six months of 2011, compared to $21.97m for the same period in 2010.
The company has reported net loss of $25.48m for the six months of 2011, compared to $22.36m for the same period in 2010.
Micromet president and CEO Christian Itin said over the past three months, they have presented initial data demonstrating blinatumomab’s high complete response rate in patients with relapsed acute lymphoblastic leukemia (ALL) and announced a new, multi-target BiTE collaboration with Amgen.
"We look forward to expanding our clinical trials in ALL and expect to release additional blinatumomab data at ASH," Itin said.